Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Progesterone versus low-dose and high-dose aspirin for elevated uterine artery resistance in early pregnancy
IRCT20160308026962N5Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of progesterone and aspirin (3 arms), sponsored by Urmia University of Medical Sciences. Primary endpoints: Change in uterine artery resistance index, Change in uterine artery pulsatility index and 1 more. Started Jan 2022; status: completed.
02
Drugs
progesteroneaspirin
Beyond the preview
Go deeper on IRCT20160308026962N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160308026962N5.